Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts

Rheumatology

Volumn 48, Issue 9, 2009, Pages 1050-1056

  Garcia Gonzalez, Estrella ^a   Selvi, Enrico ^a   Balistreri, Epifania ^a   Lorenzini, Sauro ^a   Maggio, Roberta ^a   Natale, Maria Rita ^a   Capecchi, Pier Leopoldo ^a   Lazzerini, Pietro Enea ^a   Bardelli, Marco ^a   Laghi Pasini, Franco ^a   Galeazzi, Mauro ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Cannabinoids; Fibroblasts; Fibrogenesis; Systemic sclerosis

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; BENZOXAZINE DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CTGF PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MESSENGER RNA; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ANTIFIBROGENIC ACTIVITY; APOPTOSIS; ARTICLE; BEHAVIOR DISORDER; CELL TRANSDIFFERENTIATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; EXTRACELLULAR MATRIX; FEMALE; FIBROGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; SCLERODERMA; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; DIFFUSE SCLERODERMA; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; SKIN;

AGED; APOPTOSIS; BENZOXAZINES; CANNABINOIDS; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; DRUG EVALUATION, PRECLINICAL; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; NAPHTHALENES; PHOSPHORYLATION; RECEPTORS, CANNABINOID; RNA, MESSENGER; SCLERODERMA, DIFFUSE; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 70349785531     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep189     Document Type: Article

References (37)

1. Zurier RB. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 2003;88:462-6.
2. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005;5:400-11.
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
5. Oz M. Receptor-independent effects of endocannabinoids on ion channels. Curr Pharm Des 2006;12:227-39.
6. Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1(TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci USA 2006;103:11393-8.
7. Sun Y, Bennett A. Cannabinoids: a new group of agonists of PPARs. PPAR Res 2007;2007:23513.
8. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008;105:2699-704.
9. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008;20:10-14.
10. Teixeira-Clerc F, Julien B, Grenard P et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006;12:671-6.
11. Julien B, Grenard P, Teixeira-Clerc F et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128:742-55.
12. Michalski CW, Maier M, Erkan M et al. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS ONE 2008;3:e1701.
13. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462.
14. Akhmetshina A, Dees C, Busch N et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009;60: 1129-36.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
17. Mori T, Kawara S, Shinozaki M et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 1999;181:153-9.
18. Leask A. Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Keio J Med 2004;53:74-77.
19. Sfrent-Cornateanu R, Mihai C, Balan S, Ionescu R, Moldoveanu E. The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis. J Cell Mol Med 2006;10:955-9.
20. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
21. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007;9:136-43.
22. Chen Y, Shi-Wen X, van Beek J et al. Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfatecontaining proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005;167:1699-711.
23. Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
24. Tourkina E, Gooz P, Pannu J et al. Opposing effects of protein kinase C-alpha and protein kinase C-epsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 2005;280: 13879-87.
25. Dziadzio M, Smith E, Abraham DJ et al. Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review. Clin Exp Rheumatol 2004;22:356-67.
26. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97:686-92.
27. Gallucci RM, Lee EG, Tomasek JJ. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol 2006;126:561-8.
28. Ellert-Miklaszewska A, Kaminska B, Konarska L. Cannabinoids down-regulate PI3K/akt and Erk signalling pathways and activate proapoptotic function of bad protein. Cell Signal 2005;17:25-37.
29. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 2005;41:1085-95.
30. Piomelli D, Giuffrida A, Calignano A, Rodríguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000;21:218-24.
31. Svegliati S, Cancello R, Sambo P et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005;280:36474-482.
32. Distler JH, Jüngel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
33. Akhmetshina A, Dees C, Pileckyte M et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-22.
34. Chan ES, Fernandez P, Merchant AA et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006;54:2632-42.
35. Mukherjee S, Adams M, Whiteaker K et al. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur J Pharmacol 2004;28:1-9.
36. Siegmund SV, Qian T, De Minicis S et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 2007;21:2798-806.
37. Selvi E, Lorenzini S, Garcia-Gonzalez E et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol 2008;26:574-81.